73 phenotypes from 8 alleles in 12 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Atp1a3Myk/Atp1a3+ B6NCr.129S1-Atp1a3Myk	abnormal behavior	J:180250, J:262367
	abnormal enzyme/coenzyme activity	J:180250
	abnormal gait	J:180250
	abnormal habituation	J:180250
	abnormal hippocampus pyramidal cell morphology	J:151948
	abnormal neuron physiology	J:180250
	abnormal non-rapid eye movement sleep pattern	J:180250
	abnormal paradoxical sleep pattern	J:180250
	abnormal response to novel object	J:180250
	abnormal seizure response to inducing agent	J:180250
	abnormal sensitization to xenobiotic	J:180250
	abnormal sensorimotor gating	J:180250
	abnormal sleep pattern	J:180250
	abnormal spike wave discharge	J:151948
	abnormal startle reflex	J:180250
	abnormal temporal lobe morphology	J:151948
	convulsive seizures	J:151948
	decreased anxiety-related response	J:180250
	decreased body size	J:151948
	decreased body weight	J:151948, J:262367
	decreased frequency of paradoxical sleep	J:180250
	decreased prepulse inhibition	J:180250
	enhanced conditioned place preference behavior	J:180250
	environmentally induced seizures	J:151948
	impaired contextual conditioning behavior	J:262367
	impaired coordination	J:262367
	increased locomotor activity	J:180250
	increased thigmotaxis	J:262367
	normal nervous system phenotype	J:151948
	premature death	J:151948
	prolonged circadian behavior period	J:180250
Atp1a3Myk/Atp1a3+ involves: 129S1/SvImJ * C57BL/6J * C57BL/6NCr	abnormal hippocampus pyramidal cell morphology	J:151948
	abnormal spike wave discharge	J:151948
	abnormal temporal lobe morphology	J:151948
	convulsive seizures	J:151948
	decreased body size	J:151948
	decreased body weight	J:151948
	environmentally induced seizures	J:151948
	normal nervous system phenotype	J:151948
	premature death	J:151948
Atp1a3Myk/Atp1a3+ involves: 129S1/SvImJ * C57BL/6J * C57BL/6NCr * FVB/NCr	astrocytosis	J:151948
	microgliosis	J:151948
Atp1a3Myk/Atp1a3+ Tg(Atp1a3)1Stcl/0 B6NCr.Cg-Atp1a3Myk Tg(Atp1a3)1Stcl	abnormal behavior	J:262367
	normal behavior/neurological phenotype	J:262367
	normal growth/size/body region phenotype	J:262367
	increased thigmotaxis	J:262367
Atp1a3Myk/Atp1a3+ Tg(Atp1a3)1Stcl/0 involves: 129S1/SvImJ * C57BL/6 * SJL	normal behavior/neurological phenotype	J:180250
	normal nervous system phenotype	J:151948
Atp1a3Myk/Atp1a3Myk involves: 129S1/SvImJ * C57BL/6J * C57BL/6NCr	neonatal lethality, complete penetrance	J:151948
Atp1a3Myk/Atp1a3tm1Ling involves: 129S1/SvImJ * C57BL/6J * C57BL/6NCr	premature death	J:151948
Atp1a3tm1.1Kwk/Atp1a3+ B6JJcl.Cg-Atp1a3tm1.1Kwk/Kwk	abnormal CNS synaptic transmission	J:210870
	abnormal xenobiotic pharmacokinetics	J:210870
	dystonia	J:210870
	enhanced coordination	J:210870
	hyperactivity	J:210870
	increased miniature inhibitory postsynaptic current frequency	J:210870
	normal nervous system phenotype	J:210870
Atp1a3tm1.1Kwk/Atp1a3tm1.1Kwk B6JJcl.Cg-Atp1a3tm1.1Kwk/Kwk	abnormal respiratory function	J:210870
	neonatal lethality, complete penetrance	J:210870
Atp1a3tm1.1Tmklh/Atp1a3+ B6JRj.129S1-Atp1a3tm1.1Tmklh	abnormal action potential	J:254463
	abnormal behavior	J:254463
	abnormal dentate gyrus morphology	J:254463
	abnormal habituation to a new environment	J:254463
	abnormal hippocampus granule cell morphology	J:254463
	normal behavior/neurological phenotype	J:254463
	hyperactivity	J:254463
	impaired passive avoidance behavior	J:254463
	impaired spatial learning	J:254463
	increased susceptibility to pharmacologically induced seizures	J:254463
	increased susceptibility to xenobiotic induced morbidity/mortality	J:254463
	normal nervous system phenotype	J:254463
	preweaning lethality, incomplete penetrance	J:254463
Atp1a3tm1.1Tmklh/Atp1a3tm1.1Tmklh B6JRj.129S1-Atp1a3tm1.1Tmklh	neonatal lethality, complete penetrance	J:254463
Atp1a3tm1b(EUCOMM)Hmgu/Atp1a3+ C57BL/6N-Atp1a3tm1b(EUCOMM)Hmgu/H	abnormal locomotor behavior	J:211773
	decreased anxiety-related response	J:211773
	hyperactivity	J:211773
	improved glucose tolerance	J:211773
	increased exploration in new environment	J:211773
Atp1a3tm1b(EUCOMM)Hmgu/Atp1a3tm1b(EUCOMM)Hmgu C57BL/6N-Atp1a3tm1b(EUCOMM)Hmgu/H	preweaning lethality, complete penetrance	J:211773
Atp1a3tm1Ling/Atp1a3+ involves: 129 * Black Swiss	abnormal spatial learning	J:117414
	enhanced behavioral response to addictive substance	J:117414
	normal homeostasis/metabolism phenotype	J:117414
	hyperactivity	J:117414
Atp1a3tm1Ling/Atp1a3tm1Ling involves: 129 * Black Swiss	neonatal lethality, complete penetrance	J:117414
Atp1a3tm1Mika/Atp1a3+ involves: 129S1/Sv * 129X1/SvJ * C57BL/6J	abnormal gait	J:264408
	abnormal long-term object recognition memory	J:264408
	abnormal motor capabilities/coordination/movement	J:264408
	abnormal response to novel object	J:264408
	abnormal seizure response to inducing agent	J:264408
	decreased body size	J:264408
	decreased body weight	J:264408
	decreased exploration in new environment	J:264408
	decreased locomotor activity	J:264408
	dystonia	J:264408
	hemiplegia	J:264408
	impaired coordination	J:264408
	increased kindling response	J:264408
	limb grasping	J:264408
	premature death	J:264408
	seizures	J:264408
	short stride length	J:264408
Atp1a3tm1Ute/Atp1a3+ involves: 129S1/Sv * 129X1/SvJ * C57BL/6	abnormal behavior	J:262419
	abnormal CNS synaptic transmission	J:262419
	abnormal long-term object recognition memory	J:262419
	ataxia	J:262419
	normal behavior/neurological phenotype	J:262419
	decreased anxiety-related response	J:262419
	decreased body weight	J:262419
	dystonia	J:262419
	normal growth/size/body region phenotype	J:262419
	hemiparesis	J:262419
	hemiplegia	J:262419
	hyperactivity	J:262419
	impaired coordination	J:262419
	increased kindling response	J:262419
	increased susceptibility to pharmacologically induced seizures	J:262419
	increased thermal nociceptive threshold	J:262419
	limb grasping	J:262419
	premature death	J:262419
	seizures	J:262419
	short stride length	J:262419
	tremors	J:262419
Tg(Atp1a3)1Stcl/0 B6NCr.Cg-Tg(Atp1a3)1Stcl/Stcl	abnormal behavior	J:262367
	increased freezing behavior	J:262367